SPRB director steps down; company notes no disagreement

Rhea-AI Filing Summary

Spruce Biosciences announced that director Bali Muralidhar, Ph.D. resigned from the board and the compensation committee, effective October 15, 2025. The company stated his departure was not due to any disagreement regarding operations, policies, or practices. This is a governance update with no operational or financial changes disclosed.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/17/2025 - 04:05 PM Learn about SEC filing dates

FAQ

What did SPRB disclose in this 8-K?

Spruce Biosciences reported the resignation of director Bali Muralidhar, Ph.D., effective October 15, 2025, including his departure from the compensation committee.

Was there any disagreement related to the SPRB director’s resignation?

The company stated the resignation was not the result of any disagreement on operations, policies, practices, or other matters.

What committees did the SPRB director serve on?

He served on the compensation committee and resigned from that role concurrently with his board resignation.

When did the SPRB director’s resignation take effect?

It was effective October 15, 2025.

Does this 8-K include financial or operational changes for SPRB?

No additional operational or financial changes were disclosed; this is a governance update.

Who signed the report for SPRB?

The report was signed by Samir Gharib, President and Chief Financial Officer, dated October 17, 2025.

false000168355300016835532025-10-152025-10-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2025

Spruce Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39594	81-2154263
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
611 Gateway Boulevard, Suite 740
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415-655-4168

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SPRB		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Director Departure

On October 15, 2025, Bali Muralidhar, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of his resignation as a member of the Company’s board of directors (the “Board”) and as a member of the compensation committee of the Board, effective immediately. Dr. Muralidhar’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, practices or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Spruce Biosciences, Inc.
Date: October 17, 2025				By:		/s/ Samir Gharib
						Samir Gharib
						President and Chief Financial Officer